Cost Effectiveness Analysis of Sublingual Immunotherapy in the Treatment of Patients with House Dust Mite Induced Allergic Rhinitis and Allergic Asthma Comparing with Standard Treatment in Thailand
Article Sidebar
Main Article Content
Abstract
Objective: To analyze the cost-effectiveness of sublingual immunotherapy compared with standard treatment as recommended by the National List of Essential Medicines, if used for the treatment of patients with allergic rhinitis and allergic asthma from dust mites in the Thai context. Methods Cost-effectiveness analyzes and cost-benefit assessments were used in this study. Analysis of outcomes was conducted in 3 years using the patient's perspective. All direct medical costs, direct non-medical costs and indirect medical costs in the research were based on data from the treatment in Thai context, adjusted for a 3% discount rate. Drug price in the study was median price set by the government agencies and that surveyed from physicians and patients. Quality-Adjusted Life Years (QALY), and duration of treatment are based on those reported in clinical trials. Results: Monotherapy of sublingual immunotherapy was economically cost effective for treating dust mite allergic rhinitis and asthma associated with such conditions compared to standard. ICERs (incremental cost effectiveness ratios) in 3-year of treatment were 157,928.79 and 122,849.89, 127,185.94 baht/QALY, respectively. Conclusion: Monotherapy of sublingual immunotherapy was cost effective for the treatment of allergic rhinitis caused by dust mites and asthma associated with such condition when calculating costs based on Thai context.
Article Details
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
ผลการวิจัยและความคิดเห็นที่ปรากฏในบทความถือเป็นความคิดเห็นและอยู่ในความรับผิดชอบของผู้นิพนธ์ มิใช่ความเห็นหรือความรับผิดชอบของกองบรรณาธิการ หรือคณะเภสัชศาสตร์ มหาวิทยาลัยสงขลานครินทร์ ทั้งนี้ไม่รวมความผิดพลาดอันเกิดจากการพิมพ์ บทความที่ได้รับการเผยแพร่โดยวารสารเภสัชกรรมไทยถือเป็นสิทธิ์ของวารสารฯ
References
Schatz M, Rosenwasser L. The allergic asthma phenotype. J Allergy Clin Immunol Pract. 2014; 2: 645-8.
Bunnag C, Jareoncharsri P, Tantilipikorn P, Vichya nond P, Pawankar R. Epidemiology and current status of allergic rhinitis and asthma in Thailand- ARIA Asia-Pacific Workshop report. Asian Pac J Allergy Immunol. 2009; 27: 79-86.
Sritipsukho P, Satdhabudha A, Nanthapisal S. Effect of allergic rhinitis and asthma on the quality of life in young Thai adolescents. Asian Pac J Allergy Immunol. 2015; 33: 222-6.
Vichyanond P, Sunthornchart S, Singhirannusorn V, Ruangrat S, Kaewsomboon S, Visitsunthorn N. Prevalence of asthma, allergic rhinitis and eczema among university students in Bangkok. Respir Med. 2002; 96: 34-8.
Mastrorilli C, Posa D, Cipriani F, Caffarelli C. Asthma and allergic rhinitis in childhood: what's new? Pediatr Allergy Immunol. 2016; 27: 795-803.
Huang FL, Liao EC, Yu SJ. House dust mite allergy: Its innate immune response and immunotherapy. Immu nobiology. 2018; 223: 300-2.
Wilson JM, Platts-Mills TAE. Home environmental interventions for house dust mite. J Allergy Clin Immunol Pract. 2018; 6: 1-7.
Klimek L, Bachert C, Pfaar O, Becker S, Bieber T, Brehler R, et al. ARIA guideline 2019: treatment of allergic rhinitis in the German health system. Allergol Select. 2019; 3: 22-50.
Kurukulaaratchy RJ, Zhang H, Patil V, Raza A, Karmaus W, Ewart S, et al. Identifying the heterogeneity of young adult rhinitis through cluster analysis in the Isle of Wight birth cohort. J Allergy Clin Immunol. 2015: 135: 143–50.
Ferreira-Magalhaes M, Pereira AM, Sa-Sousa A, et al. Asthma control in children is associated with nasal symptoms, obesity, and health insurance: a nationwide survey. Pediatr Allergy Immunol. 2015: 26: 466–73.
Souza-Machado A, Souza-Machado C, Silva DF, Ponte EV, Cruz AA. Causes of death in asthma patients enrolled in the Bahia State Program for the Control of Asthma and Allergic Rhinitis. J Bras Pneumol. 2007; 33: 372-9.
Brandão HV, Cruz CM, Santos Ida S Jr, Ponte EV, Guimarães A, Filho A. Hospitalizations for asthma: impact of a program for the control of asthma and allergic rhinitis in Feira de Santana. Brazil J Bras Pneumol. 2009; 35: 723-9.
Fernandes AG, Souza-Machado C, Coelho RC, Franco PA, Esquivel RM, Souza-Machado A, Cruz AA. Risk factors for death in patients with severe asthma. J Bras Pneumol. 2014; 40: 364-72.
Brożek JL, Bousquet J, Agache I, Agarwal A, Bachert C, Bosnic-Anticevich S, et al. Allergic Rhinitis and its Impact on Asthma (ARIA) guidelines-2016 revision. J Allergy Clin Immunol. 2017; 140: 950-8.
Muneswarao J, Hassali MA, Ibrahim B, Saini B, Ali IAH, Verma AK. It is time to change the way we manage mild asthma: an update in GINA 2019. Respir Res. 2019; 20: 183.
Respiratory Allergy Group of Chinese Society of Allergy; Asthma Group of Chinese Thoracic Society, Chinese Medical Association. [Chinese guidelines for the diagnosis and treatment of allergic asthma (2019, the first edition)]. Zhonghua Nei Ke Za Zhi. 2019; 58: 636-55.
Alvaro-Lozano M, Akdis CA, Akdis M, Alviani C, Angier E, Arasi S, Arzt-Gradwohl L, et al. EAACI allergen immunotherapy user's guide. Pediatr Allergy Immunol. 2020; 25: 1-101.
Dhami S, Kakourou A, Asamoah F, Agache I, Lau S, Jutel M, et al. Allergen immunotherapy for allergic asthma: A systematic review and meta-analysis. Allergy. 2017; 72: 1825-48.
Dhami S, Nurmatov U, Arasi S, Khan T, Asaria M, Zaman H, et al. Allergen immunotherapy for allergic rhinoconjunctivitis: A systematic review and meta-analysis. Allergy. 2017; 72: 1597-631.
Agache I, Lau S, Akdis CA, Smolinska S, Bonini M, Cavkaytar O, et al. EAACI guidelines on allergen immunotherapy: House dust mite-driven allergic asthma. Allergy. 2019; 74: 855-73.
Ungkhara G. Sublingual immunotherapy for allergic rhinitis. Vajira Med J. 2019; 63: 391-8.
Akkoc T, Akdis M, Akdis CA. Update in the mecha- nisms of allergen-specific immunotherapy. Allergy Asthma Immunol Res. 2011; 3: 11-20.
Demoly P, Emminger W, Rehm D, Backer V, Tom merup L, Kleine-Tebbe J. Effective treatment of house dust mite-induced allergic rhinitis with 2 doses of the SQ HDM SLIT-tablet: Results from a randomized, double-blind, placebo-controlled phase III trial. J Allergy Clin Immunol. 2016; 137: 444-51.
Virchow JC, Backer V, Kuna P, Prieto L, Nolte H, Villesen HH, Ljørring C, Riis B, de Blay F. Efficacy of a house dust mite sublingual allergen immuno therapy tablet in adults with allergic asthma: A randomized clinical trial. JAMA. 2016; 315: 1715-25.
Pharmaceutical Information Center. Standard price announcement:. Median price file according to the announcement [online]. 2020 [cited Oct 2, 2020]. Available from: dmsic.moph.go.th/index/download/8 22.
Hogan AD, Bernstein JA. GINA updated 2019: Landmark changes recommended for asthma management. Ann Allergy Asthma Immunol. 2020; 124: 311-3.
Benjaponpitak S. Research report on the clinical, quality of life and economic outcomes of long-term care in pediatric asthmatic patients in Thailand [online]. 2012 [cited Oct 2, 2020]. Available from: www.damus.in.th/damus/files/83_20120903171730_final%20report%20Asthma%20_may2012.pdf
Jeamboonsri P, Kaewsing P, Kotpat S, Kompha P, Prathumpet P, Charoensri R. Results of care for asthma patients among adults in 50th Mahavajira longkorn hospital [online]. date unknown [cited Oct 2, 2020]. Available from: www.smj.ejnal.com/e-jour nal/showdetail/showpdf.php?file_pdf=1630_02Pornthip.pdf&art_id=1630.
Cadario G, Maspoli M, Di Matteo S, Valentino MC, Oselin M, Bruno GM, et al. Health economIc evaluatIon of HDM SLIT-tablet for allergen immuno therapy in house dust mite induced allergic rhinitis with or without allergic asthma in an Italian setting. Value in Health 19: A550-1.
Ellis AK, Gagnon R, Hammerby E, Lau A. Sublingual immunotherapy tablet for the treatment of house dust mite allergic rhinitis in Canada: an alternative to minimize treatment costs? Allergy Asthma Clin Immunol. 2019; 15: 27.
Green W, Kleine-Tebbe J, Klimek L, Hahn-Pedersen J, Nørgaard Andreasen J, Taylor M. Cost-effectiveness of SQ® HDM SLIT-tablet in addition to pharmacotherapy for the treatment of house dust mite allergic rhinitis in Germany. Clinicoecon Out comes Res. 2017; 9: 77-84.
Björstad Å, Cardell LO, Hahn-Pedersen J, Svärd M. A Cost-minimisation analysis comparing sublingual immunotherapy to subcutaneous immunotherapy for the treatment of house dust mite allergy in a Swedish setting. Clin Drug Investig. 2017; 37: 541-9.
Green W, McMaster J, Babela R, Buchs S. Cost-effectiveness of the SQ HDM SLIT-tablet for the treatment of allergic asthma in three Eastern European Countries. Eur Ann Allergy Clin Immunol. 2019; 51: 68-74.
Hahn-Pedersen J, Worm M, Green W, Andreasen JN, Taylor M. Cost utility analysis of the SQ® HDM SLIT-tablet in house dust mite allergic asthma patients in a German setting. Clin Transl Allergy. 2016; 6: 35.
Health Technology and Policy Assessment Program. Health technology assessment handbook for Thailand. 2nd Edition, 2013. Bangkok: Watcharin Printing Company.
Tantilipikorn P, Chatchatee P, Chusakul S, Chanta phakul H, Thanaviratananich S, Sangsupawanich P, et al. A multi-institutional study of dust mite allergy vaccination as evidence for the treatment of moderate to severe chronic nasal allergies (2nd year). Health System Research Institute. 2019.
Nolte H, Maloney J. The global development and clinical efficacy of sublingual tablet immunotherapy for allergic diseases. Allergol Int. 2018; 67: 301-8.
Stróżek J, Samoliński BK, Kłak A, Gawińska-Drużba E, Izdebski R, Krzych-Fałta E, et al. The indirect costs of allergic diseases. Int J Occup Med Environ Health. 2019; 32: 281-90.